IVERIC bio, Inc.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 compri…
Biotechnology
US, Parsippany [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -16.61 | 15.53 | 18.63 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -13.47 | 5.01 | 5.79 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -18.42 | 3.48 | 4.27 | |
| Cash | -15.18 | 4.38 | 5.16 | |
| Capex | 28.01 | < 0.005 | < 0.005 | |
| Free Cash Flow | 6.16 | -0.37 | -0.40 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | -49.72 | -0.12 | -0.08 | |
| ROE | -54.38 | -0.15 | -0.10 | |
| ROIC | -45.39 | -0.13 | -0.09 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ISEE is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ISEE is permitted for members.
6
Leverage & Liquidity